Gene epression analyses on pre- and post-treatment samples obtained from AML patients who respond or failed to respond to Venetoclax/Decitabine treatment

To elucidate the underlying mechanisms of resistance to venetoclax and dexitabine combination therapy, we performed transcriptomic analysis of VEN/DEC pre- and post-treatment samples from AML patients enrolled in the DEC10-VEN clinical trial (NCT03404193). We have reported that AML cells from non-responders show a significant upregulation of the mRNA expression of the fatty acid metabolism activator PPARG (Peroxisome Proliferator-Activated Receptor ?) after VEN/DEC treatment. Overall design: We investigated differentially expressed genes beween AML cells obtained from responders and nonresponders